[Hicham007]

Fully agree. I might add that global non Opioid pain treatment market size will be 140.56 b$ By 2031 of which Pacira has currently less than 1 b$ and it is (and will be more.and more) developing multiple products beyond Exparel so this is clearly an overreaction and the SP will recover a subsequent part of its losses.

This is a great opportunity to buy in.

[Stockexpertpro]

PCRX 113% institution owned with 25% Float sold short Reminds me of SAVA

Buy some out of the money upside calls if there cheap

PCRX is Profitable huge revenues and growth

Income Statement
Revenue (ttm) 690.31M
Revenue Per Share (ttm) 14.88
Quarterly Revenue Growth (yoy) 5.00%
Gross Profit (ttm) N/A
EBITDA 175.34M
Net Income Avi to Common (ttm) 63.59M
Diluted EPS (ttm) 1.34

Company has over 400 Million in Cash

Book Value Per Share (mrq) 19.07 getting it for 11$ back down here all time lows for this stock with 113% institution ownership
Cash Flow Statement
Operating Cash Flow (ttm) 194.36M
Levered Free Cash Flow (ttm) 153.5M Cash flow positive

SAVA Dropped down to like 11$ then ran to 42$

[Monksdream]

PCRX over $20

[Monksdream]

PCRX still coming up from a bottom

[stockstobuy]

wow, can you imagine if we will hit even just $1 because their revenue in 2019 is monstrous.

[stockstobuy]

Wow this company only issued a small note and it doesnt exercise until Sept 2022, that if the holder will also exercise the notes because they have 18 months to do it. This is from their last 10-Q. This is imminent for a big run.

[todamoon]

Penny land coming very very fast!

[whytestocks]

News: $PCRX Why Pacira BioSciences Is Soaring Today

Shares of Pacira BioSciences (NASDAQ: PCRX) are soaring on Monday and are up by 17.5% as of 12:10 p.m. EDT, and this despite the company not reporting any news. We can attribute Pacira's good fortune to one of its potential competitors in the market for postoperative pain, Heron Therapeutic...

Got this from PCRX - Why Pacira BioSciences Is Soaring Today

[whytestocks]

News: $PCRX Pacira BioSciences Reports First Quarter 2019 Revenues of $91.3 Million

-- EXPAREL® net product sales of $90.6 million up 22.4 percent over prior year first quarter -- -- MyoScience acquisition advances leadership in non-opioid pain management; corporate name change to Pacira BioSciences reflects expanding product portfolio -- -- Conference ...

Read the whole news https://marketwirenews.com/news-releases/pacira-biosciences-reports-first-quarter-2019-revenues-of-91-3-million-8100756.html

[Lone Wolf]

Buying a few puts here. I get skeptical of biotechs that run like this just a day before earnings. Also, not sure where they're at with integrating their acquisition earlier this year...and the impact on their financials. Will they take a charge? We'll see.

$PCRX

[crudeoil24]

Pacira BioSciences shares are trading higher after competitor Heron Therapeutics' marketing application for a pain treatment was rejected by the FDA.
Benzinga

[crudeoil24]

45.50 in pre market.

[basssque]

https://www.fda.gov/newsevents/newsroom/fdainbrief/ucm604021.htm

[wiltonio]

Partner Fund Management, L.P. has filed a new 13G, reporting 5.7% ownership in $PCRX - https://fintel.io/so/us/pcrx

[stocktrademan]

PCRX bearish 36.42

[stocktrademan]

$PCRX recent news/filings

bullish 72.42
moving average breakout
gap up
bullish divergence
high volume

## source: finance.yahoo.com

Tue, 15 Dec 2015 18:20:05 GMT ~ Pacira Pharma Soars on Settled FDA Case


read full: http://finance.yahoo.com/news/pacira-pharma-soars-settled-fda-182005335.html
*********************************************************

Tue, 15 Dec 2015 17:34:00 GMT ~ Pacira Pharmaceuticals (PCRX) Stock Surges After Regulators Resolve Free Speech Dispute


read full: http://www.thestreet.com/story/13398452/1/pacira-pharmaceuticals-pcrx-stock-surges-after-regulators-resolve-free-speech-dispute.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

Tue, 15 Dec 2015 16:33:00 GMT ~ Skyepharma skips on Pacira's Exparel agreement with FDA


read full: http://uk.finance.yahoo.com/news/skyepharma-skips-paciras-exparel-agreement-163300512.html
*********************************************************

Tue, 15 Dec 2015 16:32:56 GMT ~ Pacira Pharma shares jump after FDA drops drug restriction


read full: http://sg.finance.yahoo.com/news/pacira-pharma-shares-jump-fda-163256877.html
*********************************************************

Tue, 15 Dec 2015 16:32:56 GMT ~ Pacira Pharma shares jump after FDA drops drug restriction


read full: http://finance.yahoo.com/news/pacira-pharma-shares-jump-fda-163256253.html
*********************************************************

$PCRX charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$PCRX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/PCRX/company-info
Ticker: $PCRX
OTC Market Place: Not Available
CIK code: not found
Company name: Pacira Pharmaceuticals, Inc.
Incorporated In:

Business Description:

$PCRX share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$PCRX extra dd links

Company name: Pacira Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PCRX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PCRX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PCRX+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PCRX/news - http://finance.yahoo.com/q/h?s=PCRX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PCRX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PCRX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PCRX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PCRX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Pacira+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Pacira+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Pacira+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PCRX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PCRX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PCRX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PCRX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PCRX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PCRX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PCRX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PCRX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PCRX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PCRX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PCRX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PCRX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PCRX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PCRX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PCRX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PCRX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PCRX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PCRX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PCRX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PCRX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PCRX



$PCRX DD Notes ~ http://www.ddnotesmaker.com/PCRX

[rmjackson]

Looks good. if it was going to drop it would have done so already. This wants to go some more. jumped in today!

[Lukeowl95]

Anyone else think this has the potential to bounce back? Its currently oversold at 68.81 and started to rise after market hours. Could be potential profit right here!

[TheFinalCD]

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106596431&txt2find=PCRX

http://seekingalpha.com/news/2081095-more-on-pacira-pharmaceuticals-q3-results

[maytepper]

$PCRX Brean Capital Maintains Buy On Pacira Following Visit In Manufacturing Site http://www.smarteranalyst.com/2014/10/08/brean-capital-maintains-buy-on-pacira-following-visit-in-manufacturing-site/

[maytepper]

Wedbush Reiterates Outperform On Pacira Following Stronger-Than-Expected July Estimates For EXPAREL http://www.smarteranalyst.com/2014/08/21/wedbush-reiterates-outperform-on-pacira-following-stronger-than-expected-july-estimates-for-exparel/

[stocktrademan]

Pacira Pharmaceuticals, Inc. [$PCRX] due diligence

bullish

$PCRX

DD Notes ~ http://www.ddnotesmaker.com/PCRX

##### recent news/filings ~ source: finance.yahoo.com

Fri, 27 Jun 2014 14:30:15 GMT ~ Pacira's Exparel Positive in Phase IV Studies
read full: http://finance.yahoo.com/news/paciras-exparel-positive-phase-iv-143015179.html
*********************************************************

Fri, 27 Jun 2014 11:56:55 GMT ~ Coverage initiated on Pacira Pharma by Canaccord Genuity
read full: http://finance.yahoo.com/q/ud?s=PCRX
*********************************************************

Thu, 26 Jun 2014 10:31:00 GMT ~ 6:31 am Pacira Pharma announces publication of pooled results from IMPROVE studies evaluating health economic benefits of EXPAREL; EXPAREL-based multimodal regimen was associated with significant reductions in opioid consumption, incidence
read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#pcrx
*********************************************************

Thu, 26 Jun 2014 10:30:00 GMT ~ Pacira Pharmaceuticals, Inc. Announces Publication of Pooled Results from IMPROVE Studies Evaluating Health Economic Benefits of EXPAREL®
[Business Wire] - Pacira Pharmaceuticals, Inc. today announced results from a pooled analysis of IMPROVE, a series of open-label prospective, Phase 4 clinical studies designed to compare postsurgical narcotic use and health economic outcomes associated with EXPAREL® as the foundation of a multimodal analgesic regimen versus a standard opioid-based pain management regimen.
read full: http://finance.yahoo.com/news/pacira-pharmaceuticals-inc-announces-publication-103000008.html
*********************************************************

Thu, 19 Jun 2014 13:45:00 GMT ~ Pacira Pharmaceuticals (PCRX) Reaches New Lifetime High Today
read full: http://www.thestreet.com/story/12750236/1/pacira-pharmaceuticals-pcrx-reaches-new-lifetime-high-today.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

##### chart ~ source: stockcharts.com



##### chart ~ source: eoddata.com



##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/PCRX/company-info
Ticker: $PCRX
OTC Market Place: Not Available
CIK code: not found
Company name: Pacira Pharmaceuticals, Inc.
Incorporated In:

##### extra dd links

Latest filings: http://www.otcmarkets.com/stock/PCRX/filings
Latest financials: http://www.otcmarkets.com/stock/PCRX/financials
Latest news: http://www.otcmarkets.com/stock/PCRX/news - http://finance.yahoo.com/q/h?s=PCRX+Headlines

Major holdings: http://data.cnbc.com/quotes/PCRX/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=PCRX+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/PCRX.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=PCRX

RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=PCRX&search=search

DTCC: http://search2.dtcc.com/?q=Pacira+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Pacira+Pharmaceuticals%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=Pacira+Pharmaceuticals%2C+Inc.&x=0&y=0

Short Sales: http://www.otcmarkets.com/stock/PCRX/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/PCRX/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/PCRX/research
Historical Prices: http://finance.yahoo.com/q/hp?s=PCRX+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=PCRX+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=PCRX+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=PCRX+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=PCRX+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=PCRX+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=PCRX
Balance Sheet: http://finance.yahoo.com/q/bs?s=PCRX
Cash Flow: http://finance.yahoo.com/q/cf?s=PCRX+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/PCRX
Bloomberg: http://www.bloomberg.com/quote/PCRX:US
Morningstar: http://quotes.morningstar.com/stock/s?t=PCRX
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PCRX
Barchart: http://www.barchart.com/quotes/stocks/PCRX
OTC Short Report: http://otcshortreport.com/index.php?index=PCRX
Investopedia: http://www.investopedia.com/markets/stocks/PCRX/?wa=0

http://www.pennystocktweets.com/stocks/profile/PCRX

##### last known share structure ~ source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

##### business description ~ source: otcmarkets.com



DD Notes ~ http://www.ddnotesmaker.com/PCRX
xlfv

[lady glueck]

high market cap for hi valued companies. other as blue chips pacira won't get dumped in the coming correction impo. sry for late reply but I'm rarely on boards. well, I bought long before earnings....

[tuna8377]

Pretty high market cap here, but product is great and I suspect financials tomorrow will be positive. Thoughts on buying now prior to financials or waiting to watch price action after announcement. Thx

[lady glueck]

+28% since my last call 40d ago and Pacira is still movin'

[lady glueck]

next leg UP from the IMPROVE study in laparoscopic colectomy. IMPROVE represents a series of open-label prospective Phase 4 clinical studies to assess the differences in postsurgical opioid use and health economic outcomes between patients receiving EXPAREL® (bupivacaine liposome injectable suspension) as the foundation of a multimodal analgesic regimen versus a standard opioid-based regimen for postsurgical pain control. The results were published in the January issue of Current Therapeutic Research.

[surf1944]

4:30PM Pacira Pharma: Phase 4 IMPROVE publication fids EXPAREL-based multimodal analgesia reduces opioid use, adverse events and hospital stay following laparoscopic surgery (PCRX) 57.26 +1.43 : Co announced results from the IMPROVE study in laparoscopic colectomy. IMPROVE represents a series of open-label prospective Phase 4 clinical studies to assess the differences in postsurgical opioid use and health economic outcomes between patients receiving EXPAREL (bupivacaine liposome injectable suspension) as the foundation of a multimodal analgesic regimen versus a standard opioid-based regimen for postsurgical pain control. The results were published in the January issue of Current Therapeutic Research.

The study evaluated 82 patients who underwent laparoscopic colectomy, a minimally invasive surgery to remove all or part of the colon using several small incisions in the abdomen. Compared to patients in the standard opioid-based treatment arm-who received intravenous (IV) opioids via patient-controlled analgesia (PCA) devices-patients undergoing the same procedure and receiving an EXPAREL-based multimodal regimen experienced:

A 64 mg reduction in mean opioid consumption (32 mg in the EXPAREL group compared with 96 mg in the IV opioid-based PCA group; P<0.0001)
A 1-day reduction in median length of hospital stay (3.0 days in the EXPAREL group compared with 4.0 days in the IV opioid-based PCA group; P=0.0019)
Significantly fewer opioid-related adverse events (ORAEs) (8 percent of patients in the EXPAREL group experienced ORAEs, compared with 41 percent of patients in the IV opioid-based PCA group; P=0.0019)
A $1,784 reduction in mean hospitalization costs ($11,234 in the EXPAREL group compared with $13,018 in the IV opioid-based PCA group)

[surf1944]

4:33PM Pacira Pharma: Study shows EXPAREL provided improved pain control, shorter length of hospital stay and substantial cost savings following total knee replacement (PCRX) 40.97 +0.16 : Co announced results from a 200-patient study evaluating the benefits of EXPAREL (bupivacaine liposome injectable suspension) as the foundation of a multimodal postsurgical pain management regimen in patients undergoing total knee arthroplasty (TKA), commonly known as total knee replacement. The findings show that patients treated with EXPAREL experienced better pain control with improved knee flexion and a shorter length of hospital stay compared to patients who received a femoral nerve block with a local anesthetic, the current standard of pain management for TKA. Additionally, the use of EXPAREL resulted in a substantial cost savings.

[surf1944]

8:47AM Pacira Pharma Correction: PCRX was NOT downgraded by Barclays on Friday, firm maintained Overweight and $40 tgt; prior comment has been removed (PCRX) : Correction: PCRX was NOT downgraded by Barclays on Friday, firm maintained their Overweight and $40 tgt; prior comment has been removed.